نتائج البحث - David Floch

  • يعرض 1 - 3 نتائج من 3
تنقيح النتائج
  1. 1
    Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody

    Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody حسب Abhijit Chakraborty, Stacey Tannenbaum, Christiane Rordorf, Philip J. Lowe, David Floch, Hermann Gram, Sandip Kumar Roy

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Pharmacokinetics, pharmacodynamics and safety of <scp>QGE</scp>031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects

    Pharmacokinetics, pharmacodynamics and safety of <scp>QGE</scp>031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects حسب Jonathan Arnold A. P., I. Bottoli, Andrej Skerjanec, David Floch, A. Groenewegen, Suzanne Maahs, Claire Owen, Ieuan Jones, Philip J. Lowe

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study

    Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study حسب Benjamin A. Fisher, Antónia Szántó, Wan‐Fai Ng, Stefano Bombardieri, Maximilian Posch, Athena Papas, Arwa M. Farag, Thomas Daikeler, Bettina Bannert, Diego Kyburz, Alan Kivitz, Steven E. Carsons, David Isenberg, Francesca Barone, Simon Bowman, Pascal Espié, David Floch, Cyrielle Dupuy, Xiaohui Ren, P. Faerber, A. Wright, Hans Hockey, Michael Rotte, Julie Milojevic, Alexandre Avraméas, Marie‐Anne Valentin, James S. Rush, P Gergely

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: